Identification of Genes Involved in Bladder Cancer
Identification of Genes Involved in Bladder Cancer
批准号:
7295774
负责人:
JOHN L CLIFFORD
金额:
$11.08万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-09-25 至 2010-08-31
关键词:
AgarAgeBehaviorBioinformaticsBiologicalBiological AssayBiological MarkersBiological ProcessBladderBladder TissueBladder Urothelial CellBladder UrotheliumCarcinoma in SituCell LineCellsClassCluster AnalysisCodeComplementary DNAComputer SimulationComputer softwareConditionCultured CellsDataData AnalysesData SetDatabasesDepositionDetectionDevelopmentDiagnosisDiagnosticDiseaseDistantEventGene DeliveryGene ExpressionGene Expression RegulationGenesGenomeGrowthHomologous GeneHumanImmunohistochemistryIncidenceIndividualInvasiveLarge T AntigenLengthMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of urinary bladderMediatingMethodsMicroarray AnalysisModelingMolecularMolecular ProfilingMusNumbersOntologyPatientsPremalignantPrincipal InvestigatorProcessPrognostic MarkerProtein OverexpressionRNARNA InterferenceRegulator GenesReverse Transcriptase Polymerase Chain ReactionRoleSamplingSimian virus 40Small Interfering RNASpecimenStagingStandards of Weights and MeasuresSystemTestingTimeTissuesTranscriptional RegulationTransfectionTransgenic MiceTransgenic OrganismsTransitional CellTransitional Cell CarcinomaUPK2 geneUrotheliumWeekbasebladder Carcinomabladder cancer preventionbladder transitional cell carcinomacarcinogenesisconceptdata mininggene functionin vivoknock-downmalignant statemouse modeloutcome forecastprognosticprogramspromoterresearch studytumortumor progressiontumorigenic
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Project Summary: Transitional cell carcinoma of the bladder (TCC) ranks 4th in incidence of all cancers in the developed world, yet the mechanisms of its origin and progression remain poorly understood. There are also few useful diagnostic or prognostic biomarkers for this disease. The long-term aim of this proposal is to determine molecular mechanisms involved in early and late steps in the development of TCC. In addition we hope to identify new biomarkers for detection, diagnosis and prognosis of TCC. To accomplish this we will use a mouse model for bladder cancer in which the SV40 large T antigen (SV40 T) is expressed under the control of the uroplakin promoter, which restricts expression to the bladder urothelium. These mice (UPII- SV40T) develop TCC, which is preceded by a condition resembling human CIS. The hypothesis underlying this proposal is that there are differences in gene expression profiles and gene regulatory networks between invasive TCC and CIS and between CIS and distant normal appearing urothelium, and that these changes are indicative of the malignant state. This hypothesis is based on the multistep carcinogenesis concept. An extension of our hypothesis is that CIS is an intermediate step between normal urothelium and invasive TCC and that there should be changes in gene expression corresponding to this intermediate state. The specific aims are: 1. Identify the genes and gene regulatory networks that are differentially expressed between the normal urothelium of nontransgenic and UPII-SV40T mice, CIS and TCC, using Affymetrix GeneChip(r) Arrays. The relevence of individual genes to human TCC will be validated by assessing expression of the human homologs in patient TCC and normal urothelium specimens. In silico analysis of the microarray data, which includes generating gene expression profiles (clustering analysis) and the development of promoter models based on the promoter sequences of the differentially expressed genes will be performed. 2. Assess the function and potential relevance to bladder carcinogenesis of these genes in vivo by stable overexpression, or siRNA-mediated suppression, of the validated genes in human bladder-derived cell lines. Relevence: Completion of these studies should advance our understanding of the molecular events underlying TCC development. In addition, the identification of genes differentially expressed between normal urothelium, CIS and TCC will provide much needed diagnostic and prognostic markers for this disease.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1186/1471-2407-10-394
发表时间:
2010-07-26
期刊:
BMC cancer
影响因子:
3.8
作者:
[Kleiner-Hancock HE, Shi R, Remeika A, Robbins D, Prince M, Gill JN, Syed Z, Adegboyega P, Mathis JM, Clifford JL]
通讯作者:
Clifford JL
HGF/c-met/Stat3 signaling during skin tumor cell invasion: indications for a positive feedback loop.
DOI:
10.1186/1471-2407-11-180
发表时间:
2011-05-19
期刊:
BMC cancer
影响因子:
3.8
作者:
[Syed ZA, Yin W, Hughes K, Gill JN, Shi R, Clifford JL]
通讯作者:
Clifford JL
Identification of Genes Involved in Bladder Cancer
-
批准号:7211280
-
项目类别:
-
资助金额:$12.58万
-
财政年份:2006
-
负责人:JOHN L CLIFFORD
-
依托单位:
RETINOID RECEPTOR FUNCTION IN SKIN CANCER PROGRESSION
-
批准号:2896591
-
项目类别:
-
资助金额:$10.57万
-
财政年份:1998
-
负责人:JOHN L CLIFFORD
-
依托单位:
RETINOID RECEPTOR FUNCTION IN SKIN CANCER PROGRESSION
-
批准号:2680107
-
项目类别:
-
资助金额:$10.57万
-
财政年份:1998
-
负责人:JOHN L CLIFFORD
-
依托单位:
RETINOID RECEPTOR FUNCTION IN SKIN CANCER PROGRESSION
-
批准号:6513293
-
项目类别:
-
资助金额:$4.14万
-
财政年份:1998
-
负责人:JOHN L CLIFFORD
-
依托单位:
RETINOID RECEPTOR FUNCTION IN SKIN CANCER PROGRESSION
-
批准号:6802658
-
项目类别:
-
资助金额:$6.43万
-
财政年份:1998
-
负责人:JOHN L CLIFFORD
-
依托单位:
RETINOID RECEPTOR FUNCTION IN SKIN CANCER PROGRESSION
-
批准号:6376867
-
项目类别:
-
资助金额:$10.57万
-
财政年份:1998
-
负责人:JOHN L CLIFFORD
-
依托单位:
RETINOID RECEPTOR FUNCTION IN SKIN CANCER PROGRESSION
-
批准号:6173954
-
项目类别:
-
资助金额:$10.57万
-
财政年份:1998
-
负责人:JOHN L CLIFFORD
-
依托单位:
RETINOIC ACID RECEPTOR AND CELLULAR DIFFERENTIATION
-
批准号:2170353
-
项目类别:
-
资助金额:$2.56万
-
财政年份:1995
-
负责人:JOHN L CLIFFORD
-
依托单位:
RETINOIC ACID RECEPTOR AND CELLULAR DIFFERENTIATION
-
批准号:2170354
-
项目类别:
-
资助金额:$0.3万
-
财政年份:1995
-
负责人:JOHN L CLIFFORD
-
依托单位:
RETINOIC ACID RECEPTOR AND CELLULAR DIFFERENTIATION
-
批准号:2467547
-
项目类别:
-
资助金额:$0.06万
-
财政年份:1995
-
负责人:JOHN L CLIFFORD
-
依托单位:
RETINOIC ACID RECEPTOR AND CELLULAR DIFFERENTIATION
-
批准号:2170352
-
项目类别:
-
资助金额:$0.3万
-
财政年份:1994
-
负责人:JOHN L CLIFFORD
-
依托单位:
RETINOIC ACID RECEPTOR AND CELLULAR DIFFERENTIATION
-
批准号:2170351
-
项目类别:
-
资助金额:$2.07万
-
财政年份:1994
-
负责人:JOHN L CLIFFORD
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: